



**FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS**  
**La Haute Marche**  
**Javené BP 90203**  
**35302 FOUGERES cedex**  
**FRANCE**

**DECENTRALISED PROCEDURE**

**PUBLICLY AVAILABLE ASSESSMENT REPORT  
FOR A VETERINARY MEDICINAL PRODUCT**

**FR/V/0247/001/DC:**

**ATIPAZOLE 5 mg/ml Solution for injection for dogs and cats**  
[BE, BG, DE, HU, LT, LV, NL, PL, SI, UK]

**ANTIDORM 5 mg/ml Solution for injection for dogs and cats**  
[ES, FR, IT, PT]

**FR/V/0248/001/DC: TIPAFAR 5 mg/ml Solution for injection for dogs and cats**  
[AT / DE / ES / FR/ PT/ UK]

**FR/V/0249/001/DC: NOSEDORM 5 mg/ml Solution for injection for dogs and cats**  
[DE / ES / FR / PT]

**Date: 29/08/2013**

*French agency for food, environmental and occupational health safety– French Agency for Veterinary Medicinal Products*  
La Haute Marche – Javené BP 90203 - 35302 Fougères Cédex - Téléphone : + 33 (0)2 99 94 78 78 - Télécopie : + 33 (0)2 99 94 78 99 -

[www.anses.fr](http://www.anses.fr)

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

**MODULE 1****PRODUCT SUMMARY**

EU Procedure number Name, strength and pharmaceutical form	<p>FR/V/0247/001/DC:  ATIPAZOLE 5 mg/ml Solution for injection for dogs and cats  [BE, BG, DE, HU, LT, LV, NL, PL, SI, UK ]  ANTIDORM 5 mg/ml Solution for injection for dogs and cats [ES, FR, IT, PT]</p> <p>FR/V/0248/001/DC:  TIPAFAR 5 mg/ml Solution for injection for dogs and cats  [AT / DE / ES / FR/ PT/ UK]</p> <p>FR/V/0249/001/DC:  NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE / ES / FR / PT]</p>
Applicant	VETPHARMA ANIMAL HEALTH SL C/ Les Corts, 23. 08028 BARCELONA SPAIN
Active substance(s)	Atipamezole hydrochloride
ATC Vetcode	QV03AB90
Target species	Dogs and Cats
Indication for use	Atipamezole hydrochloride is a selective $\alpha_2$ antagonist and indicated for reversal of the sedative effects of medetomidine and dexmedetomidine in dogs and cats.

**MODULE 2**

The Summary of Product Characteristics (SPC) for this product is available on the website <http://www.anmv.anses.fr/>

**MODULE 3**

**PUBLIC ASSESSMENT REPORT**

Legal basis of original application	Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	26/06/2013
Concerned Member States for original procedure	FR/V/0247/001/DC: ATIPAZOLE 5 mg/ml Solution for injection for dogs and cats [BE, BG, DE, HU, LT, LV, NL, PL, SI, UK ] ANTIDORM 5 mg/ml Solution for injection for dogs and cats [ES, FR, IT, PT]  FR/V/0248/001/DC: TIPAFAR 5 mg/ml Solution for injection for dogs and cats [AT / DE / ES / FR/ PT/ UK]  FR/V/0249/001/DC: NOSEDORM 5 mg/ml Solution for injection for dogs and cats [DE / ES / FR / PT]

**I. SCIENTIFIC OVERVIEW**

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

**II. QUALITY ASPECTS****A. Composition**

The product contains 4.27 mg/ml of atipamezole (hydrochloride) and excipients methylparahydroxybenzoate, sodium chloride, water for injections.

The container/closure system is a glass vial fitted with a rubber stopper. The particulars of the containers and controls performed are provided and conform to the regulation.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

**B. Method of the Product**

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

**Preparation**

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

### **C. Control of Starting Materials**

The active substance is atipamezole hydrochloride, an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

### **D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

### **E. Control on intermediate products**

Not applicable.

### **F. Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

### **G. Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

An in-use shelf-life as detailed on the SPC has been supported by appropriate data.

### **H. Genetically Modified Organisms**

Not applicable.

### **J. Other Information**

Not applicable.

### III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

#### III.A Safety Testing

##### *Pharmacological Studies*

The test product is bioequivalent to the reference product, ANTISEDAN 5 MG/ML Solution for injection for dogs and cats marketed by Orion Corporation. An exemption from the requirement to provide a bioequivalence study was accepted as formulations of the tested and the reference products are similar.

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

##### *Toxicological Studies*

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

##### *User Safety*

The formulations of the tested and the reference products are similar. Warnings and precautions of the reference product SPC have been applied to the tested product SPC and are adequate to ensure safety to users of the product.

##### *Ecotoxicity*

The applicant has provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

#### III.B Residues documentation

Not applicable. These products are intended for non-food producing species.

### IV. CLINICAL ASSESSMENT (EFFICACY)

#### IV.A Pre-Clinical Studies

##### *Tolerance in the Target Species of Animals*

The applicant has not provided a tolerance study which is acceptable because the tested product and the reference product are bioequivalent and their formulations are similar.

#### IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, studies are not

"This product was originally authorised under an EU procedure prior to 1<sup>st</sup> January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

efficacy required. The

efficacy claims of the tested product are based on the reference product documentation.

## **V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.